Em meio à busca humana por respostas diante de uma pandemia que desafiou certezas, um estudo malaio com quinhentos pacientes veio reafirmar o que a ciência vinha sinalizando: a ivermectina não protege contra a progressão da COVID-19. Mais do que confirmar sua ineficácia, a pesquisa revelou que o medicamento pode causar danos reais — especialmente para os mais vulneráveis. É um lembrete de que a esperança, quando desvinculada da evidência, pode se tornar um risco em si mesma.
Olhar Digital
· Feb 21, 2022
· health
· 1 min de lectura
High
Verificación: Verificado
Malaysian study confirms ivermectin ineffective for COVID-19, linked to severe adverse effects
Study participants experienced severe adverse events including acute diarrhea with fluid loss and myocardial infarction cases; 13 deaths occurred though not attributed to ivermectin.
◉
Health & Medicine
2722 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% coincidencia
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Cobertura Relacionada
G1 · Aug 19
Macaé mobiliza 45 salas para atualizar vacinação de menores de 15 anos
Macaé lança campanha de atualização vacinal para menores de 15 anos em 45 pontos de saúde até 1º de setembro, com Dia D …
Agência FAPESP · Aug 19 Pesquisadores desenvolvem vacina inteligente contra chikungunya com vírus que se replica apenas uma vezCientistas da USP criaram uma vacina inovadora contra chikungunya usando vírus geneticamente modificado que se replica a…
G1 · Aug 19 Pastor belga do Senado é afastado após atacar veterinária que segue em estado graveVeterinária terceirizada sofre ataque grave de pastor belga malinois no Senado Federal em Brasília, com mordida no pesco…
Rádio Pampa · Aug 19 Heterossexuais são maioria entre pacientes que descobrem HIV em estágio avançadoEstudo em hospital de Porto Alegre revela que 84% dos pacientes diagnosticados com HIV em estágio avançado são heterosse…
Impacto Geopolítico
🌎
Malaysian COVID-19 study confirms ivermectin ineffectiveness and safety concerns; primarily a public health finding with limited geopolitical significance.
Escalation Risk
low
Confidence
HIGH
Sesgo y Encuadre
⚖
Article presents Malaysian study findings on ivermectin with straightforward reporting of ineffectiveness and adverse effects, with minimal apparent bias in presentation.
Bias Direction
center
Confidence
MED
Evidence-based reporting: The article frames ivermectin through clinical trial results, emphasizing both ineffectiveness and safety concerns. Uses direct researcher quotes and specific data points (500 patients, 33 adverse events) to support conclusions.
inútil (useless)
quadro de diarreia grave (severe diarrhea condition)
levanta preocupações (raises concerns)
Statements from ivermectin proponents or alternative medicine advocates
Discussion of ivermectin's approved uses in other conditions
Context on why some populations pursued ivermectin despite limited evidence
Perspective from manufacturers or researchers who previously studied ivermectin for COVID-19
Lente Económico
📈
Malaysian study of 500 COVID-19 patients confirms ivermectin ineffective for disease prevention with significant adverse effects, particularly severe diarrhea, raising public health concerns about unsupervised off-label use.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical/Drug Manufacturing
Healthcare Services
Medical Research
Public Health Administration
Retail Pharmacy
Consumers who purchased ivermectin for COVID-19 treatment face wasted expenditure on an ineffective treatment with documented health risks. This undermines consumer confidence in self-medication and off-label drug use, potentially increasing demand for proven treatments and medical consultations.
Regulatory bodies should strengthen enforcement against off-label ivermectin promotion for COVID-19, implement stricter controls on unsupervised pharmaceutical distribution, and increase public education campaigns. Healthcare systems may need to address treatment costs for adverse effects and establish clearer guidelines for approved COVID-19 therapeutics.